Genmab — April 2016
-
-
I q3 var other oncology på 20m og i q4 var other oncology på 29,3m (Darzalex fratrukket). Det svarer til ca. 46,5 % stigning på other oncology (Dazalex fratrukket). Jeg anser det ikke for sandsynligt at other oncology (Darzalex fratrukket) har en nul-væskt i q1, men nok nærmere det de havde i forrige quarter. Dvs. at other oncology (Darazalex fratrukket) er på ca. 43m og q1 var 145m (inkl Darzalex). Derfor tror jeg, at q1 salg for Darzalex er på ca. 102m (ex off label)
-
JJ CC er igang - der ser dog ikke ud til at være nogen info om dara i præsentationsmaterialet
-
CC vil tage en time
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
